ARTICLE | Company News
Minophagen, onepharm deal
November 5, 2007 8:00 AM UTC
onepharm received exclusive rights to develop and market Minophagen's OPM-3001 in Europe and the U.S. to treat influenza infection. onepharm expects to start a Phase II trial of the compound derived f...